Introduction
LL-37 is the only member of the cathelicidin family of antimicrobial peptides expressed in humans. It is a 37-amino acid peptide derived from the cleavage of the precursor protein hCAP18, and it serves as one of the body's most versatile innate immune defenders. Named for its leucine-leucine (LL) N-terminal sequence and 37-amino acid length, LL-37 is produced by neutrophils, macrophages, epithelial cells, and keratinocytes in response to infection, injury, and inflammation.
Beyond its direct antimicrobial activity, LL-37 plays critical roles in immune modulation, wound healing, angiogenesis, and the regulation of inflammatory responses. In integrative medicine, LL-37 deficiency is increasingly recognized as a contributor to chronic infections, inflammatory skin conditions, respiratory disease, and impaired wound healing.
Root Causes of LL-37 Deficiency
LL-37 production is tightly regulated by vitamin D, making vitamin D deficiency one of the most common and correctable causes of low LL-37 activity. Additional factors that suppress LL-37 include:
- Vitamin D deficiency: The gene encoding hCAP18/LL-37 contains a vitamin D response element (VDRE), making LL-37 synthesis directly dependent on adequate vitamin D3 levels. Deficiency is the single most impactful driver of reduced LL-37 in most populations.
- Chronic infections: Persistent bacterial and viral pathogens — including Mycobacterium tuberculosis, Staphylococcus aureus, and certain viruses — have evolved mechanisms to suppress LL-37 expression, facilitating immune evasion.
- Inflammatory skin conditions: In atopic dermatitis (eczema), LL-37 expression is paradoxically suppressed despite chronic inflammation, leaving the skin barrier vulnerable to secondary infections.
- Gut dysbiosis: Disruption of the intestinal microbiome reduces colonocyte production of LL-37, impairing mucosal immunity and increasing susceptibility to enteric pathogens.
- Aging: LL-37 production declines with age, contributing to increased infection susceptibility, impaired wound healing, and chronic low-grade inflammation in older adults.
- Zinc deficiency: Zinc is a cofactor for LL-37 processing and activity. Deficiency impairs both its synthesis and antimicrobial efficacy.
- Obesity and metabolic syndrome: Adipose tissue inflammation and insulin resistance are associated with reduced cathelicidin expression and impaired innate immune responses.
Biological Mechanisms
Direct Antimicrobial Activity
LL-37 disrupts microbial membranes through electrostatic interactions — its cationic, amphipathic helical structure binds to negatively charged bacterial, fungal, and viral membranes, causing membrane destabilization and lysis. This mechanism is effective against a broad spectrum of pathogens including gram-positive and gram-negative bacteria, fungi, enveloped viruses, and mycobacteria, with a low propensity for resistance development.
Immune Modulation and Chemotaxis
LL-37 acts as a chemoattractant for neutrophils, monocytes, and T-cells, recruiting immune cells to sites of infection and injury. It activates dendritic cells and macrophages, bridging innate and adaptive immunity. Critically, LL-37 modulates rather than simply amplifies inflammation — it can suppress excessive LPS-induced inflammatory responses by neutralizing lipopolysaccharide (LPS), preventing septic shock-like cytokine cascades.
Wound Healing and Angiogenesis
LL-37 promotes keratinocyte migration and proliferation, accelerating re-epithelialization of wounds. It stimulates angiogenesis by upregulating VEGF (vascular endothelial growth factor) and FGF (fibroblast growth factor), supporting new blood vessel formation essential for tissue repair. These properties make it particularly relevant in chronic wound and diabetic ulcer contexts.
Biofilm Disruption
One of LL-37's most clinically significant properties is its ability to disrupt and prevent bacterial biofilm formation — a major mechanism of antibiotic resistance. LL-37 penetrates established biofilms and inhibits their formation, making it a promising adjunct in chronic biofilm-associated infections such as chronic sinusitis, UTIs, and implant-associated infections.
Antiviral Activity
LL-37 exhibits direct antiviral activity against enveloped viruses including influenza, HIV, RSV, and SARS-CoV-2. It disrupts viral envelopes and inhibits viral entry into host cells. Vitamin D-mediated upregulation of LL-37 is one proposed mechanism underlying the association between vitamin D sufficiency and reduced respiratory viral infection severity.
Autophagy Induction
LL-37 induces autophagy in macrophages, enhancing intracellular pathogen clearance — particularly relevant for mycobacterial infections where pathogens survive within macrophage phagosomes. This mechanism is central to its role in tuberculosis immunity.
Gut Mucosal Defense
In the intestinal epithelium, LL-37 maintains the mucosal barrier by suppressing pathogen adhesion, modulating the gut microbiome composition, and regulating intestinal inflammatory responses. Low colonic LL-37 is associated with increased susceptibility to Clostridioides difficile and inflammatory bowel disease.
Clinical Applications
Recurrent Respiratory Infections
Low LL-37 — often driven by vitamin D deficiency — is associated with increased susceptibility to respiratory infections including influenza, pneumonia, and COVID-19. Optimizing vitamin D to restore LL-37 is a foundational intervention in recurrent respiratory infection protocols.
Chronic Skin Conditions
In atopic dermatitis, psoriasis, and rosacea, LL-37 dysregulation plays a central pathogenic role. In eczema, deficient LL-37 leaves the skin vulnerable to Staphylococcus aureus colonization. In rosacea and psoriasis, excessive or aberrant LL-37 processing drives inflammatory cascades — making context-specific modulation essential.
Chronic and Biofilm-Associated Infections
LL-37's biofilm-disrupting properties make it relevant in chronic sinusitis, recurrent UTIs, Lyme disease co-infections, and implant-associated infections where conventional antibiotics fail due to biofilm protection.
Wound Healing
Topical and systemic LL-37 protocols are being investigated for chronic wounds, diabetic ulcers, and post-surgical healing, leveraging its keratinocyte-stimulating and angiogenic properties.
Gut Health and IBD
Restoring LL-37 through vitamin D optimization and microbiome support is an emerging strategy in inflammatory bowel disease and recurrent enteric infections.
Integrative Protocols
Vitamin D Optimization
The most evidence-based intervention for restoring LL-37 is optimizing vitamin D3 levels to 60–80 ng/mL (150–200 nmol/L). This typically requires 5,000–10,000 IU/day of vitamin D3 with cofactors (vitamin K2, magnesium) and should be guided by serum 25(OH)D testing.
Peptide Therapy
Exogenous LL-37 peptide is used in research and integrative clinical settings, typically via subcutaneous injection or topical application for skin and wound indications. Dosing protocols vary by indication and are typically individualized under clinical supervision.
Synergistic Combinations
- Thymosin Alpha-1: Combines T-cell immune restoration with LL-37's innate antimicrobial defense for comprehensive immune support.
- BPC-157: Pairs gut mucosal repair with LL-37's intestinal defense mechanisms.
- Zinc: Essential cofactor for LL-37 processing and antimicrobial efficacy.
- Vitamin A: Synergizes with vitamin D in regulating cathelicidin expression in epithelial tissues.
- Probiotics (Lactobacillus rhamnosus, Bifidobacterium): Support gut microbiome diversity and colonocyte LL-37 production.
Monitoring
Key labs include serum 25(OH)D, zinc, complete immune panel, inflammatory markers (CRP, IL-6), and pathogen-specific testing where indicated. For skin conditions, clinical photography and symptom scoring provide important outcome tracking.
Safety and Contraindications
LL-37 has a strong safety profile in research settings. At physiological concentrations it is well tolerated; at supraphysiological doses it can cause cytotoxicity to host cells, underscoring the importance of appropriate dosing. In rosacea and psoriasis, where aberrant LL-37 processing drives inflammation, indiscriminate upregulation may worsen symptoms — these conditions require careful clinical assessment before LL-37 protocols are initiated.
Vitamin D optimization, the primary indirect approach to raising LL-37, is safe when monitored with regular serum testing and cofactor support.
Conclusion
LL-37 is a cornerstone of human innate immunity — bridging antimicrobial defense, immune modulation, wound healing, and mucosal protection. Its dependence on vitamin D makes deficiency both common and highly correctable. Whether addressing recurrent infections, chronic wounds, biofilm-associated disease, or gut mucosal dysfunction, restoring LL-37 activity through targeted nutritional and peptide protocols offers a powerful, physiologically grounded approach to immune resilience.